<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">636295</article-id><article-id pub-id-type="doi">10.26442/20795696.2024.3.202932</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Potential and perspectives of local application of hyaluronic acid in vulvovaginal atrophy in women of reproductive age: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности и перспективы локального применения гиалуроновой кислоты при вульвовагинальной атрофии у женщин репродуктивного возраста</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3993-7629</contrib-id><name-alternatives><name xml:lang="en"><surname>Prilepskaya</surname><given-names>Vera N.</given-names></name><name xml:lang="ru"><surname>Прилепская</surname><given-names>Вера Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. поликлиническим отд-нием</p></bio><email>v_prilepskaya@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9499-7654</contrib-id><name-alternatives><name xml:lang="en"><surname>Nazarova</surname><given-names>Niso M.</given-names></name><name xml:lang="ru"><surname>Назарова</surname><given-names>Нисо Мирзоевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, вед. науч. сотр.</p></bio><email>n_nazarova@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1742-7555</contrib-id><name-alternatives><name xml:lang="en"><surname>Devyatkina</surname><given-names>Anastasia R.</given-names></name><name xml:lang="ru"><surname>Девяткина</surname><given-names>Анастасия Романовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident</p></bio><bio xml:lang="ru"><p>ординатор</p></bio><email>grinasta26@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8243-5272</contrib-id><name-alternatives><name xml:lang="en"><surname>Abakarova</surname><given-names>Patimat R.</given-names></name><name xml:lang="ru"><surname>Абакарова</surname><given-names>Патимат Рапиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. научно-поликлинического отд-ния</p></bio><email>p_abakarova@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2977-9065</contrib-id><name-alternatives><name xml:lang="en"><surname>Mezhevitinova</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Межевитинова</surname><given-names>Елена Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, вед. науч. сотр. научно-поликлинического отд-ния</p></bio><email>mejevitinova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-20" publication-format="electronic"><day>20</day><month>09</month><year>2024</year></pub-date><volume>26</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>254</fpage><lpage>259</lpage><history><date date-type="received" iso-8601-date="2024-09-20"><day>20</day><month>09</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-09-20"><day>20</day><month>09</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/636295">https://gynecology.orscience.ru/2079-5831/article/view/636295</self-uri><abstract xml:lang="en"><p>Disruption of the structure and function of the vulvovaginal epithelium in women of reproductive age is accompanied by impaired sexual function and a decrease in the quality of life. This review analyses research on the use of hyaluronic acid (HA) for women of reproductive age with conditions and diseases manifesting as vulvovaginal atrophy. HA is involved in various physiological processes, including tissue regeneration, cell migration and proliferation during inflammation, and helps maintain water balance and tissue integrity. Local therapy with HA is effective in treating the symptoms of vulvovaginal atrophy in women of reproductive age associated with hypoestrogenism, both as a monotherapy and in combination with other treatments. It improves sexual function and quality of life, helping women to improve their sexual lives and living standards.</p></abstract><trans-abstract xml:lang="ru"><p>Нарушение структуры и функции вульвовагинального эпителия у женщин репродуктивного возраста сопровождается снижением сексуальной функции и качества жизни. В представленном обзоре проведен анализ данных исследований по применению гиалуроновой кислоты (ГК) у женщин репродуктивного возраста с различными состояниями и заболеваниями, проявляющимися вульвовагинальной атрофией. ГК участвует в различных физиологических процессах в организме, регенерации тканей, миграции и пролиферации клеток при воспалении, помогает поддерживать водный баланс и целостность структуры тканей. Локальная терапия ГК эффективна в отношении всех симптомов вульвовагинальной атрофии у женщин репродуктивного возраста, связанных с гипоэстрогенией, как в форме монотерапии, так и при комбинированном лечении, способствуя улучшению сексуальной функции и повышению качества жизни.</p></trans-abstract><kwd-group xml:lang="en"><kwd>vulvovaginal atrophy</kwd><kwd>hyaluronic acid</kwd><kwd>genitourinary menopausal syndrome</kwd><kwd>dermatoses</kwd><kwd>intrauterine adhesions</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вульвовагинальная атрофия</kwd><kwd>гиалуроновая кислота</kwd><kwd>генитоуринарный менопаузальный синдром</kwd><kwd>дерматозы</kwd><kwd>внутриматочные синехии</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-8. DOI:10.1097/GME.0000000000000329</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lev-Sagie A. Vulvar and vaginal atrophy: Physiology, clinical presentation, and treatment considerations. Clin Obs Gynecol. 2015;58(3):476-91. DOI:10.1097/GRF.0000000000000126</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. DOI:10.4065/mcp.2009.0413</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (Kaunas). 2019;55(10):615. DOI:10.3390/medicina55100615</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl. 1):45-51. DOI:10.1016/s0090-4295(03)00676-9</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Escobar C, Rosenblum N. Vaginal estrogen – what a urologist should know. Urology. 2021;151:37-43. DOI:10.1016/j.urology.2020.05.034</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bayer IS. Hyaluronic acid and controlled release: A review. Molecules. 2020;25(11):2649. DOI:10.3390/molecules25112649</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-39. DOI:10.1038/nrc1391</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7):701. DOI:10.3390/polym10070701</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Leeman LM, Rogers RG. Sex after childbirth: Postpartum sexual function. Obstet Gynecol. 2012;119(3):647-55. DOI:10.1097/AOG.0b013e3182479611</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Banaei M, Azizi M, Moridi A, et al. Sexual dysfunction and related factors in pregnancy and postpartum: A systematic review and meta-analysis protocol. Syst Rev. 2019;8(1):161. DOI:10.1186/s13643-019-1079-4</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rowland M, Foxcroft L, Hopman WM, Patel R. Breastfeeding and sexuality immediately postpartum. Can Fam Physician. 2005;51(10):1366-7. PMID:16926969</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Agarwal SK, Kim J, Korst LM, Hughes CL. Application of the estrogen threshold hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med. 2015;10(2):77-83. DOI:10.1089/bfm.2014.0030</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Gustavino C, Sala P, Cusini N, et al. Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: A prospective randomised clinical trial. Ann Med. 2021;53(1):1589-97. DOI:10.1080/07853890.2021.1974083</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Менопауза и климактерическое состояние у женщины. Клинические рекомендации РОАГ. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/117_2. Ссылка активна на 16.05.2024 [Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii ROAG. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2. Accessed: 16.05.2024 (in Russian)].</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ekin M, Yaşar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539-43. DOI:10.1007/s00404-010-1382-8</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jokar A, Davari T, Asadi N, et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: A randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4(1):69-78. PMID:26793732</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565-71. DOI:10.1080/13697137.2019.1643180</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220-3. DOI:10.1016/j.contraception.2006.03.022</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Handy AB, McMahon LN, Goldstein I, Meston CM. Reduction in genital sexual arousal varies by type of oral contraceptive pill. J Sex Med. 2023;20(8):1094-102. doi:10.1093/jsxmed/qdad072</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Cotangco K, Class QA, Johnson TP, Kothari R. Cervical cancer survivors' attitudes and understanding of menopause and hormone therapy. Menopause. 2020;27(6):701-5. DOI:10.1097/GME.0000000000001520</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European Countries. Breast Care (Basel). 2019;14(6):344-53. DOI:10.1159/000503219</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol. 2022;13(2):71-100. DOI:10.5306/wjco.v13.i2.71</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647-61. DOI:10.1210/jc.2017-01138</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Kingsberg SA, Larkin L, Krychman M, et al. WISDOM survey: Attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26(2):124-31. DOI:10.1097/GME.0000000000001194</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. DOI:10.1097/GME.0000000000001609</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol. 2010;62(4):331-47. PMID:20827250</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Casey PM, MacLaughlin KL, Faubion SS. Impact of contraception on female sexual function. J Womens Health (Larchmt). 2017;26(3):207-13. DOI:10.1089/jwh.2015.5703</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Журавлева Ю.А., Прохорова О.В., Гептинг Н.А., и др. Женская сексуальность и комбинированные оральные контрацептивы: проблемы и возможности коррекции. Российский вестник акушера-гинеколога. 2020;20(6):101-6 [Zhuravleva JA, Prokhorova OV, Gepting NA, et al. Female sexuality and combined oral contraceptive pills: Administration and correction issues. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(6):101-6 (in Russian)]. DOI:10.17116/rosakush202020061101</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar lichen sclerosus: Current perspectives. Int J Womens Health. 2020;12:11-20. DOI:10.2147/IJWH.S191200</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: A scoping review. Obstet Gynecol Int. 2020;2020:7480754. DOI:10.1155/2020/7480754</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Шперлинг Н.В., Шперлинг М.И. Лечение и профилактика рецидивирования склероатрофического лихена половых органов у женщин. Акушерство и гинекология. 2022;12:70-8 [Shperling NV, Shperling MI. Treatment and prevention of recurrent genital lichen sclerosus in women. Obstetrics and Gynecology. 2022;12:70-8 (in Russian)]. DOI:10.18565/aig.2022.280</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952-72. DOI:10.1111/jdv.18102</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Лишай красный плоский. Клинические рекомендации. 2020. Режим доступа: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Ссылка активна на 16.05.2024 [Lishai krasnyi ploskii. Klinicheskie rekomendatsii. 2020. Available at: https://cnikvi.ru/docs/klinicheskie-rekomendacii/КР%20КПЛ%202020.docx. Accessed: 16.05.2024 (in Russian)].</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-6. DOI:10.1046 j.1365-2133.2000.03473.x</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-14. DOI:10.1111/j.1365-2133.2011.10449.x</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Dreisler E, Kjer JJ. Asherman's syndrome: Current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-8. DOI:10.2147/IJWH.S165474</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Lee WL, Liu CH, Cheng M, et al. Focus on the primary prevention of intrauterine adhesions: Current concept and vision. Int J Mol Sci. 2021;22(10):5175. DOI:10.3390/ijms22105175</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Tafti SZG, Javaheri A, Firoozabadi RD, et al. Role of hyaluronic acid intrauterine injection in the prevention of Asherman's syndrome in women undergoing uterine septum resection: An RCT. Int J Reprod Biomed. 2021;19(4):339-46. DOI:10.18502/ijrm.v19i4.9060</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Huang CY, Chang WH, Cheng M, et al. Crosslinked hyaluronic acid gels for the prevention of intrauterine adhesions after a hysteroscopic myomectomy in women with submucosal myomas: A prospective, randomized, controlled trial. Life (Basel). 2020;10(5):67. DOI:10.3390life10050067</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Wang YQ, Song XH, Wu SL, et al. Comparison of autocross-linked hyaluronic acid gel and intrauterine device for preventing intrauterine adhesions in infertile patients: A randomized clinical trial. Gynecol Minim Invasive Ther. 2020;9(2):74-80. DOI:10.4103/GMIT.GMIT_103_19</mixed-citation></ref></ref-list></back></article>
